How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 1979-1985

  Van Der Heijde, Désirée ^a   Landewé, Robert ^a   Van Der Linden, Sjef ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANKYLOSING SPONDYLITIS; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; MEASUREMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELIABILITY; REVIEW; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

DISEASE PROGRESSION; HEALTH STATUS; HUMANS; RADIOLOGY; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 22244454100     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21133     Document Type: Review

References (27)

1. Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis: a systematic literature review. J Rheumatol 2001;28: 1056-62.
2. Chorus AM, Miedema HS, Boonen A, van der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003;62:1178-84.
3. Ward MM. Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 1998;24:815-27.
4. Landewe R, Wanders AJ, Mielants H, Dougados M, van der Heijde D. Function in patients with ankylosing spondylitis is the resultant of patient reported disease activity and radiographic damage of the spine [abstract]. Ann Rheum Dis 2004;63 Suppl 1:88-9.
5. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
6. Van der Heijde D, Wanders AJ, Mielants H, Dougados M, Landewe R. Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004;63 Suppl 1:88.
7. Bruynesteyn K, Landewe R, van der Linden S, van der Heijde D. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months follow-up. Ann Rheum Dis 2004;63:1413-8.
8. Van der Heijde D, Landewe R, Spoorenberg A, Wanders A, van der Linden S, de Vlam K, et al. Can a historical cohort of patients with ankylosing spondylitis containing data of 2-year radiographic progression serve as a control group to assess inhibition of structural damage by TNF-blockers? [abstract]. Arthritis Rheum 2003;48 Suppl 9:S441.
9. Wanders AJ, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005;52:1756-65.
10. Kidding A, van der Linden S, Boers M, Gielen X, de Witte L, Kester A, et al. Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 1993;6:117-25.
11. Van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001;45:430-8.
12. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
13. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
14. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
15. Van der Heijde D, Dougados M, Davis DA, Weisman MH, Maksymowych W, Braun J, et al, and the ASessment in Ankylosing Spondylitis International Working Group. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386-94.
16. Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing [editorial]. Arthritis Rheum 2003;48:1-5.
17. MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
18. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996;35:373-6.
19. Creemers M, Franssen M, Hof M, Gribnau F, van de Putte L, van Riel P. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64: 127-9.
20. Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50: 2622-32.
21. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
22. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004;3:CD004524.
23. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al, and the ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis [review]. Ann Rheum Dis 2003;62:817-24.
24. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046-55.
25. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
27. Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50:699-706.